These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Omalizumab: a recombinant humanized anti-IgE antibody for allergic asthma. Ruffin CG; Busch BE Am J Health Syst Pharm; 2004 Jul; 61(14):1449-59. PubMed ID: 15332692 [TBL] [Abstract][Full Text] [Related]
5. Spotlight on omalizumab in allergic asthma. Bang LM; Plosker GL BioDrugs; 2004; 18(6):415-8. PubMed ID: 15571425 [TBL] [Abstract][Full Text] [Related]
6. Omalizumab: not only for asthma. Ben-Shoshan M Recent Pat Inflamm Allergy Drug Discov; 2008 Nov; 2(3):191-201. PubMed ID: 19076009 [TBL] [Abstract][Full Text] [Related]
7. Omalizumab: a review of its use in the management of allergic asthma. Bang LM; Plosker GL Treat Respir Med; 2004; 3(3):183-99. PubMed ID: 15219177 [TBL] [Abstract][Full Text] [Related]
8. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Milgrom H; Berger W; Nayak A; Gupta N; Pollard S; McAlary M; Taylor AF; Rohane P Pediatrics; 2001 Aug; 108(2):E36. PubMed ID: 11483846 [TBL] [Abstract][Full Text] [Related]
9. Omalizumab : other indications and unanswered questions. Mankad VS; Burks AW Clin Rev Allergy Immunol; 2005 Aug; 29(1):17-30. PubMed ID: 16222081 [TBL] [Abstract][Full Text] [Related]
10. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. Lanier B; Bridges T; Kulus M; Taylor AF; Berhane I; Vidaurre CF J Allergy Clin Immunol; 2009 Dec; 124(6):1210-6. PubMed ID: 19910033 [TBL] [Abstract][Full Text] [Related]
12. Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis. Nayak A; Casale T; Miller SD; Condemi J; McAlary M; Fowler-Taylor A; Della Cioppa G; Gupta N Allergy Asthma Proc; 2003; 24(5):323-9. PubMed ID: 14619332 [TBL] [Abstract][Full Text] [Related]
13. Omalizumab: an update on efficacy and safety in moderate-to-severe allergic asthma. Chipps BE; Figliomeni M; Spector S Allergy Asthma Proc; 2012; 33(5):377-85. PubMed ID: 23026179 [TBL] [Abstract][Full Text] [Related]
14. Anti-IgE for chronic asthma in adults and children. Walker S; Monteil M; Phelan K; Lasserson TJ; Walters EH Cochrane Database Syst Rev; 2004; (3):CD003559. PubMed ID: 15266491 [TBL] [Abstract][Full Text] [Related]
15. Anti-IgE monoclonal antibody (omalizumab) in the treatment of atopic asthma and allergic respiratory diseases. D'Amato G; Liccardi G; Noschese P; Salzillo A; D'Amato M; Cazzola M Curr Drug Targets Inflamm Allergy; 2004 Sep; 3(3):227-9. PubMed ID: 15379589 [TBL] [Abstract][Full Text] [Related]
16. Omalizumab in asthma: approval and postapproval experience. Chiang DT; Clark J; Casale TB Clin Rev Allergy Immunol; 2005 Aug; 29(1):3-16. PubMed ID: 16222080 [TBL] [Abstract][Full Text] [Related]
17. Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody. Silkoff PE; Romero FA; Gupta N; Townley RG; Milgrom H Pediatrics; 2004 Apr; 113(4):e308-12. PubMed ID: 15060258 [TBL] [Abstract][Full Text] [Related]
18. Treating atopic asthma with the anti-IgE monoclonal antibody. D'Amato G Monaldi Arch Chest Dis; 2002 Apr; 57(2):117-9. PubMed ID: 12357840 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Berger W; Gupta N; McAlary M; Fowler-Taylor A Ann Allergy Asthma Immunol; 2003 Aug; 91(2):182-8. PubMed ID: 12952113 [TBL] [Abstract][Full Text] [Related]
20. Anti-IgE monoclonal antibody: a new approach to the treatment of allergic respiratory diseases. D'Amato G; Oldani V; Donner CF Monaldi Arch Chest Dis; 2003; 59(1):25-9. PubMed ID: 14533279 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]